Study guide

17.2 Medication Reconciliation & Duplicate Therapy

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

17.2 Medication Reconciliation & Duplicate Therapy

Key Takeaways Explain This Topic AI

Medication reconciliation must be performed at admission, transfer, and discharge using at least two sources to build the Best Possible Medication History (BPMH)

Common discrepancies are omitted medicines, duplicated therapy, wrong dose, and wrong frequency — each must be reconciled and resolved with the prescriber

Duplicate therapy includes two drugs from the same therapeutic class (two NSAIDs, two ACE inhibitors) or the same active ingredient under different names

Additive toxicity from duplicate therapy includes renal failure and GI bleed with two NSAIDs, serotonin syndrome with two serotonergic agents, and hyperkalaemia with two ACE inhibitors or ARBs

Last updated: August 2026

Medication Reconciliation

Medication reconciliation is the formal process of creating the most accurate possible list of every medicine a patient is taking, comparing that list against each new prescription, and resolving discrepancies. The DHA blueprint expects pharmacists to perform reconciliation at three trigger points: admission, transfer, and discharge .

Building the Best Possible Medication History (BPMH)

The Best Possible Medication History (BPMH) is the foundation of reconciliation. It must be built using at least two sources , because patient self-report alone misses refill gaps, stopped medicines, and forgetfulness. Acceptable source pairs include:

  • Patient or caregiver interview plus a community pharmacy refill record
  • Patient interview plus a prior hospital discharge summary
  • Pharmacy refill record plus the previous primary-care prescription list

The BPMH captures each drug's name, dose, route, frequency, last dose taken, and indication , plus any over-the-counter medicines, herbal products, vitamins, and PRN agents the patient uses. Allergies and prior adverse reactions are recorded at the same time.

Discrepancy Types

Once the BPMH is built, it is compared against the active inpatient or discharge order set. Four discrepancy categories appear repeatedly on the exam:

Discrepancy Example Resolution

Omission Patient's home metoprolol not ordered on admission Contact prescriber; clarify whether to continue, hold, or stop

  • Duplication Both omeprazole (home) and esomeprazole (new) ordered Stop one; flag as same-class duplicate
  • Wrong dose Home amiodarone 200 mg daily, ordered as 100 mg daily Confirm intended dose change with prescriber

Wrong frequency Home allopurinol 100 mg daily, ordered as 100 mg twice daily Clarify; gout prophylaxis is usually once daily

Every discrepancy must be documented, communicated to the prescriber, and resolved before the medicine is dispensed. Silent correction by the pharmacist is not acceptable — the prescriber must be contacted.

Reconciliation at Each Trigger Point

Admission : compare home medicines against admission orders; decide continue/hold/stop for each.

Transfer (e.g. ICU to ward, or service-to-service): reconcile medicines as orders are rewritten; watch for medicines dropped during handover (e.g. VTE prophylaxis, stress ulcer prophylaxis).

Discharge : reconcile discharge prescriptions against the inpatient record AND the BPMH; ensure the patient leaves with a clear, written list of what to take, what was stopped, and what was changed. Counsel the patient on changes.

Duplicate Therapy

Duplicate therapy occurs when a patient receives two medicines that are either from the same therapeutic class or contain the same active ingredient under different names . It is one of the most common preventable causes of adverse drug events in both community and inpatient settings.

Same-Class Duplicates

  • Duplicate Pair Risk
  • Two NSAIDs (ibuprofen + diclofenac; naproxen + celecoxib) Additive GI bleed, renal impairment, fluid retention
  • Two ACE inhibitors (enalapril + lisinopril) Additive hyperkalaemia, hypotension, acute kidney injury

ACE inhibitor + ARB (ramipril + valsartan) Hyperkalaemia, renal dysfunction — combination generally discouraged

Two PPIs (omeprazole + esomeprazole; lansoprazole + pantoprazole) No added benefit; Clostridioides difficile and fracture risk; magnesium depletion

Two serotonergic agents (SSRI + tramadol; SSRI + SNRI; sertraline + linezolid) Serotonin syndrome — agitation, clonus, hyperreflexia, hyperthermia

  • Two anticoagulants (rivaroxaban + warfarin without bridging intent) Major bleeding
  • Two diuretics without monitoring (furosemide + hydrochlorothiazide) Hypokalaemia, hyponatraemia, dehydration
  • Same-Active-Ingredient Duplicates

These occur when a patient is prescribed a brand and a generic, or two brands, of the same molecule without realising:

Panadol (paracetamol 500 mg) + Co-codamol (paracetamol + codeine) — cumulative paracetamol hepatotoxicity.

Brufen (ibuprofen) + Nurofen (ibuprofen) — duplicate NSAID.

Glucophage (metformin) + a metformin-containing combination (e.g. Janumet) — duplicate metformin, GI and lactic acidosis risk.

Clinical Red Flags the Pharmacist Must Catch

Serotonin syndrome from two serotonergic agents: triad of clonus, hyperreflexia, agitation ± hyperthermia. Onset is usually within hours of adding the second agent.

GI bleed from two NSAIDs: melena, haematemesis, drop in haemoglobin.

Hyperkalaemia from dual RAAS blockade: peaked T waves, cardiac arrhythmia.

Hepatotoxicity from duplicate paracetamol: rising ALT/AST, jaundice; daily paracetamol intake should stay below 4 g in adults.

The Pharmacist's Workflow for Duplicate Detection

Maintain an active problem list and drug list for each patient.

On every new prescription, screen by therapeutic class (ATC code level 3–4) and by active ingredient .

When a duplicate is identified, contact the prescriber with the specific risk rather than refusing to dispense silently.

Document the intervention and outcome.

A common exam stem shows a patient admitted on sertraline who is then started on tramadol for post-operative pain. The correct pharmacist action is to flag the serotonin syndrome risk and recommend a non-serotonergic analgesic (e.g. paracetamol, morphine).

Exam Trap — Hidden Duplicates at Discharge

A frequent DHA trap gives a discharge prescription list that looks clean until you cross-check the BPMH. The patient was admitted on Panadol (paracetamol 500 mg) and is discharged with Co-codamol (paracetamol 500 mg + codeine 30 mg) plus a PRN paracetamol order — three sources of paracetamol, easily exceeding the 4 g/day adult ceiling and risking hepatotoxicity. The pharmacist must total the daily paracetamol load across all products (prescribed, OTC, and combination) before dispensing, and either consolidate the order or counsel the patient to avoid OTC paracetamol. The same trap appears with ibuprofen dispensed as Brufen alongside an OTC Nurofen the patient was already taking.